These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 26935918)
1. Analysis of the entry mechanism of Crimean-Congo hemorrhagic fever virus, using a vesicular stomatitis virus pseudotyping system. Suda Y; Fukushi S; Tani H; Murakami S; Saijo M; Horimoto T; Shimojima M Arch Virol; 2016 Jun; 161(6):1447-54. PubMed ID: 26935918 [TBL] [Abstract][Full Text] [Related]
2. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice. Hinkula J; Devignot S; Åkerström S; Karlberg H; Wattrang E; Bereczky S; Mousavi-Jazi M; Risinger C; Lindegren G; Vernersson C; Paweska J; van Vuren PJ; Blixt O; Brun A; Weber F; Mirazimi A J Virol; 2017 May; 91(10):. PubMed ID: 28250124 [TBL] [Abstract][Full Text] [Related]
4. Development of a vesicular stomatitis virus pseudotyped with herpes B virus glycoproteins and its application in a neutralizing antibody detection assay. Kinoshita H; Yamada S; Ogawa T; Nguyen PHA; Harada S; Kawahara M; Ishijima K; Maeda K; Ebihara H; Fukushi S mBio; 2024 Jul; 15(7):e0109224. PubMed ID: 38847539 [TBL] [Abstract][Full Text] [Related]
5. Crimean-Congo hemorrhagic fever virus replication imposes hyper-lipidation of MAP1LC3 in epithelial cells. Moroso M; Verlhac P; Ferraris O; Rozières A; Carbonnelle C; Mély S; Endtz HP; Peyrefitte CN; Paranhos-Baccalà G; Viret C; Faure M Autophagy; 2020 Oct; 16(10):1858-1870. PubMed ID: 31905032 [TBL] [Abstract][Full Text] [Related]
6. Characterization of Glycoprotein-Mediated Entry of Severe Fever with Thrombocytopenia Syndrome Virus. Tani H; Shimojima M; Fukushi S; Yoshikawa T; Fukuma A; Taniguchi S; Morikawa S; Saijo M J Virol; 2016 Jun; 90(11):5292-5301. PubMed ID: 26984731 [TBL] [Abstract][Full Text] [Related]
7. Pseudo-plaque reduction neutralization test (PPRNT) for the measurement of neutralizing antibodies to Crimean-Congo hemorrhagic fever virus. Canakoglu N; Berber E; Ertek M; Yoruk MD; Tonbak S; Bolat Y; Aktas M; Kalkan A; Ozdarendeli A Virol J; 2013 Jan; 10():6. PubMed ID: 23282186 [TBL] [Abstract][Full Text] [Related]
13. Biosafety standards for working with Crimean-Congo hemorrhagic fever virus. Weidmann M; Avsic-Zupanc T; Bino S; Bouloy M; Burt F; Chinikar S; Christova I; Dedushaj I; El-Sanousi A; Elaldi N; Hewson R; Hufert FT; Humolli I; Jansen van Vuren P; Koçak Tufan Z; Korukluoglu G; Lyssen P; Mirazimi A; Neyts J; Niedrig M; Ozkul A; Papa A; Paweska J; Sall AA; Schmaljohn CS; Swanepoel R; Uyar Y; Weber F; Zeller H J Gen Virol; 2016 Nov; 97(11):2799-2808. PubMed ID: 27667586 [TBL] [Abstract][Full Text] [Related]
14. Fine mapping epitope on glycoprotein Gc from Crimean-Congo hemorrhagic fever virus. Zhang J; Simayi A; Wang M; Moming A; Xu W; Wang C; Li Y; Ding J; Deng F; Zhang Y; Sun S Comp Immunol Microbiol Infect Dis; 2019 Dec; 67():101371. PubMed ID: 31627038 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the cell culture based and the mouse brain derived inactivated vaccines against Crimean-Congo hemorrhagic fever virus in transiently immune-suppressed (IS) mouse model. Pavel STI; Yetiskin H; Kalkan A; Ozdarendeli A PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008834. PubMed ID: 33226988 [TBL] [Abstract][Full Text] [Related]